Abstract-Hypertensive disorders of pregnancy are a leading cause of maternal and perinatal morbidity and mortality.
H ypertensive disorders of pregnancy (HDP), including gestational hypertension, preeclampsia (PE), and HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, complicate 5% to 6% of pregnancies in the United States and are a leading cause of maternal and perinatal morbidity and mortality. 1, 2 Clinically, PE is a multisystem disorder that is characterized by new-onset hypertension (HTN) and either proteinuria or signs of organ impairment after 20 weeks of gestation. 3 Chronic HTN (CHTN) refers to HTN that is diagnosed before pregnancy or within the first 20 gestational weeks of pregnancy. 3 Compared with normotensive women, women with CHTN have a 6-fold increased risk of developing preeclampsia superimposed on their underlying chronic HTN. 4 PE is associated with impaired angiogenesis and immunologic alterations in the early placental microenvironment. The process of trophoblast invasion and remodeling of the spiral arteries in a normal pregnancy relies heavily on the maternal immune system. 5 Estrogen-induced downregulation of B lymphopoiesis is one such adaptation. [6] [7] [8] [9] Impairment of this regulatory mechanism may jeopardize the pregnancy by permitting maintenance or expansion of alloreactive B cells and the attendant production of deleterious alloantibodies. Indeed, elevated numbers of maternal B cells have been found in the setting of preeclampsia. 10, 11 Furthermore, a subset of B cells produce angiotensin type-1 receptor (AT1-AA), which has been implicated in the pathogenesis of PE. 10 BAFF (B-cell activating factor, also known as B-lymphocyte stimulator) is a potent B-cell survival and differentiation factor. 12 Inadequate levels of BAFF lead to decreases in mature B cells, whereas excessive BAFF levels promote expansion of B cells.
BAFF has undergone limited investigation in pregnancy. Given the importance of suppression of B lymphopoiesis to development of a normal pregnancy, 8 we hypothesized that the dysregulation of BAFF contributes to abnormalities in placental implantation that are associated with the development of HDP. Furthermore, we also hypothesized that elevated maternal serum BAFF levels serve as an early serological harbinger of HDP, thereby enabling risk stratification of women for prenatal surveillance. The objectives of our study were (1) to November 2017 describe maternal serum BAFF levels in normal pregnancies and (2) to evaluate the relationship between first-trimester serum BAFF levels and development of HDP. To our knowledge, this is the first longitudinal study of maternal serum BAFF levels in human pregnancy.
Materials and Methods
We performed a prospective observational study of pregnant women presenting for prenatal care at Los Angeles County+University of Southern California Obstetrics clinics. Subjects were recruited from October 2011 through June 2013. Pregnant women were recruited at the time of their first prenatal visit. Women under the age of 18 and women carrying a fetus with a known major congenital anomaly were excluded. Women with diagnosed chronic medical or rheumatic diseases (eg, diabetes mellitus and lupus) were enrolled, but only results from healthy women without chronic medical or rheumatic conditions and women with CHTN are included in the present report. A control group of premenopausal nonpregnant (NP) women without known medical or rheumatic illnesses was recruited from the Los Angeles County+University of Southern California Gynecology outpatient clinics. Informed consent was obtained from each study participant before enrollment. Approval for this study was obtained from the Los Angeles County+University of Southern California Institutional Review Board.
A woman was classified as having gestational hypertension if she had ≥2 episodes of new-onset HTN (systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg) after 20 weeks of pregnancy. PE was defined as gestational hypertension that was accompanied by proteinuria of at least 300 mg in a 24-hour urine collection or a protein/creatinine ratio ≥0.3. HELLP syndrome was diagnosed when a woman had laboratory evidence of hemolysis, a platelet count <100,000/μL, and serum levels of aspartate aminotransferase and alanine aminotransferase that were greater than or equal to twice normal values. Superimposed preeclampsia was diagnosed in a woman with CHTN when she experienced an acute exacerbation of hypertension after 20 weeks of gestation. In a woman without preexisting proteinuria, new-onset proteinuria was also required for the diagnosis. 3 Patient characteristics were obtained through patient interviews and medical chart review. Maternal venous blood was collected by venipuncture at least once per trimester, on admission for delivery, and postpartum. The first trimester was defined as <14 gestational weeks, the second trimester as 14 0/7 to 27 6/7 gestational weeks, and the third trimester as 28 0/7 gestational weeks to delivery. Postpartum samples were collected before hospital discharge after delivery.
Blood samples were collected in sterile tubes without additives and refrigerated until processing. Sera were routinely isolated from the clotted blood samples within 12 to 24 hours and were aliquotted and stored at −80°C. Once all samples had been collected, aliquots were shipped overnight on dry ice to two of the authors (J.M. and K.K.) for analysis. Serum BAFF levels were measured in a blinded fashion using a sandwich ELISA (R&D Systems cat# DBLYS0B). Samples were diluted 1:3 using the diluent supplied with the kit. Fifty µL of the sample or standard (supplied with the kit) were dispensed into the precoated ELISA plate in duplicate. The plate was incubated at room temperature for 3 hours. The plate was washed with buffer (0.02 mol/L Tris, 0.15 mol/L NaCl, 0.1% Tween 20) to remove unbound sample. The prediluted horseradish peroxidase-conjugated anti-BAFF secondary antibody (supplied with the kit) was dispensed into each well and incubated at room temperature for 1 hour. The plate was washed as above, and the tetramethylbenzidine substrate (supplied with the kit) was added. After color development, the substrate reaction was stopped with 2 N sulfuric acid. The absorbance 450 nm was read on a Molecular Devices SprectrMax 340 plate reader, and the sample concentration was back calculated using SoftMaxPro5.4.1 software and a 4-parameter curve fit. All BAFF levels are reported as ng/mL.
Statistical Analysis
Subjects with ectopic gestations or in whom laboratory data were not available were excluded. All remaining subjects were included in the analyses describing serum BAFF levels in pregnancy and postpartum. Because many of the serum samples were drawn at the same time as were routine prenatal laboratory tests, many subjects had >1 serum sample obtained in any given trimester of pregnancy. For standardization, the first serum sample associated with each time period (first, second, and third trimester, and postpartum) was selected for analysis. If a value for any individual time period was missing for a given subject, then that subject was excluded from analysis for that time period. Clinical variables that were independently associated with serum BAFF levels (P<0.10) were included as potential covariates in multiple logistic regression models.
For analyses testing the association between first-trimester serum BAFF levels and HDP, only subjects capable of developing the outcome of HDP were included. Accordingly, subjects with elective terminations of pregnancy, with spontaneous abortion (pregnancy loss before 20 gestational weeks), who were lost to follow-up, or who had no first-trimester serum BAFF level were excluded. Patient historical and demographic characteristics that were independently associated with serum BAFF levels or HDP (P<0.10) were included as potential covariates in multiple logistic regression models. χ 2 or Fisher exact testing was used for categorical variables, and Kruskal-Wallis or signed-ranks testing was used for all continuous variables. All tests were 2-sided, with a P value <0.05 considered statistically significant. Means are expressed as ± the SD. Medians are presented for data not normally distributed. Calculations were performed using SAS (SAS version 9.2; SAS Institute, Cary, NC) or SigmaStat software (SPSS).
Results

Subject Demographics
A total of 222 women are included in this report: 149 healthy pregnant women, 25 pregnant women with CHTN, and 48 NP controls ( Figure 1 ). Their demographic and clinical characteristics are presented in Table. The great majority (>80%) of subjects in each group was of Hispanic ethnicity, and no difference in frequency of nulliparity was appreciated between the 3 groups. Although maternal body mass index was numerically higher in the CHTN group, this was not statistically different from the body mass indexes in either the healthy pregnant group or the NP control group. The maternal age of the healthy pregnant group was lower than that of the other 2 groups (P=0.001), but maternal age did not correlate with BAFF serum levels in any of these 3 groups. 
Serum BAFF Levels During Pregnancy
Because the elevated serum levels of BAFF among individuals with various inflammatory or autoimmune conditions [13] [14] [15] [16] could potentially confound changes associated with pregnancy, we focused our longitudinal study on women who, at the onset of pregnancy, were free of any chronic disease. Compared with serum BAFF levels among the NP control subjects, first-trimester serum BAFF levels among the healthy pregnant subjects were significantly reduced (median, 1.00 versus 0.90 ng/ mL; Figure 2A ). During the course of their pregnancies, serum BAFF levels steadily declined, with second-trimester levels significantly lower than the corresponding first-trimester levels (median, 0.77 versus 0.90 ng/mL) and third-trimester levels significantly lower than the corresponding second-trimester levels (median, 0.72 versus 0.77 ng/mL; Figure 2B ). By a median of 2 days postpartum, serum BAFF levels had rebounded (median, 0.87 ng/mL) and were similar to first-trimester levels. Of note, these levels were still significantly lower than those in the NP cohort (P=0.011), suggesting that restoration of serum BAFF levels to prepregnancy levels requires >2 days.
Occurrence of HDP and Relation to Serum BAFF Levels
After excluding normotensive women who electively terminated their pregnancies, whose pregnancies ended in spontaneous abortion (miscarriage <20 completed weeks of gestation), and whose first-trimester serum BAFF levels or pregnancy outcome were not available, 115 healthy subjects remained ( Figure 1 
246).
The median (25th-75th interquartile range) gestational age at delivery for all subjects with HDP was 38.3 (36.3-39.6), which was not significantly different from the median (25th-75th interquartile range) gestational age of 39.0 (38.1-39.9) at delivery for all subjects without HDP (P=0.340).
Strikingly, first-trimester serum BAFF levels were significantly greater in healthy subjects who subsequently developed HDP than in those who remained normotensive (median, 1.02 versus 0.85 ng/mL; Figure 3A) . The difference in serum BAFF levels between subjects who did or did not develop HDP persisted throughout pregnancy. Serum BAFF levels declined as the pregnancies progressed, with levels remaining significantly greater in HDP subjects than in non-HDP subjects during both the second trimester (median, 0.92 versus 0.75 ng/mL for HDP and non-HDP subjects, respectively) and third trimester (median, 0.85 versus 0.71 ng/mL for HDP and non-HDP subjects, respectively; Figure 3B ). In both subgroups, postpartum levels rapidly rose, with serum BAFF levels remaining numerically greater in those subjects who developed HDP than in those who did not develop HDP.
Receiver operating characteristic curve analysis for development of HDP (Figure 4 ) indicated that a serum BAFF level cutoff of 0.775 ng/mL had a high sensitivity (92.9%) but a low specificity (40.6%). Increasing the serum BAFF level cutoff to 0.895 ng/mL substantially improved the specificity (57.4%) with only a modest decline in sensitivity (85.7%). Further increase of the cutoff level to 0.945 ng/mL again substantially improved the specificity (70.3%), although sensitivity declined to 71.4%. Increasing the cutoff level even higher to 1.005 ng/mL only modestly improved specificity (78.2%) but resulted in a considerable drop in sensitivity (57.1%).
Serum BAFF Levels in Pregnant Women With CHTN
The significant association between increased first-trimester serum BAFF level and development of HDP raised the possibility that an elevated serum BAFF level may reflect an underlying diathesis to development of HTN, perhaps related to inflammatory changes in the vasculature or to persistent survival of B cells that secrete pathogenic autoantibodies. In a phenotypically normotensive woman with such underlying diathesis, the stress of an advancing pregnancy may aggravate this prehypertensive state (as reflected by an elevated first-trimester serum BAFF level) to the point where HTN becomes clinically apparent. If correct, then pregnant women with CHTN, who not only share an underlying diathesis to development of HTN but also have already crossed the threshold to phenotypic HTN, should harbor elevated serum BAFF levels as well.
To address this possibility, we measured first-trimester serum BAFF levels in the 25 pregnant women with CHTN enrolled in our study. In these women, first-trimester serum BAFF levels were significantly elevated compared with corresponding levels in healthy women who did not develop HDP (median, 0.96 versus 0.85 ng/mL; P=0.001), but they were similar to first-trimester serum levels in healthy women who ultimately developed HDP (median, 0.96 versus 1.02 ng/ mL; P=0.692). Of the 25 women with CHTN, 13 (52%) developed superimposed preeclampsia, and there was no difference in first-trimester serum BAFF levels between women with CHTN who did or did not develop superimposed preeclampsia (P=0.327).
Discussion
Given the importance of BAFF to B-cell survival and differentiation, regulation of BAFF may be critical in modulating B cells in a healthy pregnancy. In this study, we found that maternal serum BAFF levels decrease with advancing gestation and return to early pregnancy levels shortly after delivery. Importantly, we found that increased first-trimester serum BAFF level was associated with HDP and, therefore, could potentially serve as an early biomarker of this common and clinically morbid obstetric condition.
In our study, serum BAFF levels were lower in the first trimester of pregnancy compared with NP controls. Serum BAFF levels among healthy pregnant women further declined in the second and third trimesters of pregnancy compared with those in the first trimester. These findings are consistent with those recently reported in a murine model, in which serum BAFF levels, as well as the number of B cells in blood and spleen, decreased as gestation advanced. 17 Our findings are also consistent with placental studies, in which human placental BAFF expression was higher in the first trimester compared with that in the third trimester. 18 These findings suggest that although BAFF may need to be suppressed in pregnancy compared with the NP state, a certain level of BAFF may be important early in the pregnancy to guarantee sufficient number of protective B cells against deleterious infectious agents. Once the pregnancy has been established and as it advances, BAFF may need to be downregulated to ensure quiescence of autoreactive/alloreactive B cells to maintain the pregnancy. In mice, autoreactive B cells are much more dependent on BAFF for their survival than are nonautoreactive B cells, 19, 20 and a similar dichotomy may plausibly exist in humans as well.
Although there may be a vital physiological need for some BAFF in early pregnancy, excessive serum BAFF levels at this time may be deleterious to pregnancy outcomes. We found a positive association between first-trimester maternal serum BAFF levels and HDP. This association persisted throughout the second and third trimesters, with higher serum BAFF levels found in healthy women who developed HDP compared with those who did not.
Preeclampsia has long been thought to be related to dysregulation of the maternal immune system, and our findings are consistent with this hypothesis. Maternal agonistic autoantibodies to the AT1-AA have been correlated with disease severity in women with preeclampsia. 21, 22 Jensen et al 10 demonstrated that CD19+CD5+ B cells produce AT1-AA and found increased levels of this B-cell subtype in the peripheral blood and the placentas of women with preeclampsia. Of note, Figure 2A . B, Composite serum BAFF levels during the indicated trimesters or postpartum (PP) are plotted. The circles indicate the medians for subjects who did not develop HDP, and the squares indicate the medians for subjects who did develop HDP. The error bars indicate the 25th and 75th percentiles. For non-HDP subjects, N=101, 83, 88, and 72, respectively, for first trimester, second trimester, third trimester, and postpartum samples. For HDP subjects, N=14, 11, 13, and 12, respectively, for first trimester, second trimester, third trimester, and postpartum samples. *P=0.012; **P=0.002; ***P=0.020. BAFF promotes survival of murine CD19+CD5+B cells. 23 These findings, taken together with ours, suggest a plausible link between BAFF and the pathogenesis of preeclampsianamely, that an increase in BAFF expression leads to enhanced survival of B cells, including autoreactive B cells that produce the deleterious autoantibodies that have been associated with preeclampsia.
This notion is supported by our finding that first-trimester serum BAFF levels were similar between women with CHTN and healthy women who ultimately developed HDP. AT1-AA are associated with preeclampsia and with hypertensive conditions outside of pregnancy. 24, 25 Chan et al 26 further noted that BAFF and B-cell activation are necessary for the development of angiotensin-induced HTN in a NP murine model. Additionally, it is well established that women who develop HDP have an increased risk of developing hypertension outside of pregnancy. 27, 28 Thus, the immune dysregulation at play in women with clinically apparent CHTN may be the same dysregulation that exists in women destined to develop HDP even while they remain clinically asymptomatic. If this hypothesis is corroborated, then elevated BAFF levels may reflect not only a pathological predisposition to hypertension during pregnancy but also postpartum.
Because our study addressed the association of maternal serum BAFF level with development of HDP, we are unable to determine whether an elevated first-trimester maternal serum BAFF level is a potential biomarker for development of HDP or whether elevated maternal serum BAFF levels actually contribute to the pathophysiologic process(es). Our study-the first to longitudinally assess maternal serum BAFF levels across pregnancy-was relatively small, and only 14 women developed HDP in our cohort. If our findings are corroborated by future investigations, then an elevated maternal serum BAFF level may be clinically helpful in assessing the likelihood of HDP and in counseling women accordingly. We did not evaluate placental expression of BAFF in our study, and, therefore, it remains uncertain whether the increase in maternal serum BAFF in women with HDP arises from the placenta, fetus, mother, or a combination of the three.
Markers other than maternal serum BAFF level have been proposed as predictors of preeclampsia or its associated disorders. 29, 30 In contrast to our findings, the previous putative predictors of HDP were routinely noted in the second and third trimesters of pregnancy, times at which interventions for risk modification are limited. [31] [32] [33] [34] Our finding of elevated serum BAFF levels among women who ultimately developed HDP is, thus, unique in that this elevation can be detected even during the first trimester. Identification of BAFF as an early biomarker for HDP may permit early risk stratification of the pregnancy which, in turn, could allow for the initiation of preventive measures in the first or early second trimester, before trophoblast invasion is complete. 35 The area under the curve 95% confidence interval generated by receiver operating characteristic curve analysis for development of HDP went as high as 0.846, suggesting that first-trimester serum BAFF level may be a clinically useful early predictor of HDP. Additional studies to confirm these initial observations are vitally needed.
Furthermore, unlike many of the other biomarkers for preeclampsia that are related to endothelial dysfunction and coagulation activation, the proposed pathophysiologic mechanism for an association between BAFF and HDP is immune maladaptation. Because HDP is likely the result of the confluence of multiple aberrant processes rather than one distinct pathological pathway, 22 a true predictor of disease is likely to involve multiple biomarkers, of which serum BAFF may be one. Future studies should incorporate AT1-AA, B-cell subtypes, and other markers of inflammation to better understand the pathophysiology of preeclampsia and develop a better biomarker-perhaps one that includes a combination of 2 or 3 of these parameters-than stand-alone BAFF.
HDP is associated with a myriad of clinical characteristics, including maternal age, nulliparity, and obesity. BAFF has similarly been found to be elevated among obese individuals. 14, 36 However, there were no statistically significant differences in these clinical characteristics between the women who developed HDP versus those who did not. Accordingly, we do not think that clinical factors can explain the significant elevation in first-trimester serum BAFF levels among women who develop HDP.
The primary strengths of our study are the large number of healthy subjects in our cohort, the single-center design in which clinical care was relatively uniform, and the prospective study design in which women were followed through all trimesters of pregnancy. Our study was constrained by the small number of women who ultimately developed HDP, so our findings need to be independently replicated before definitive conclusions can be drawn. Additionally, our subjects were primarily of Hispanic ethnicity. Cheema et al 37 noted that serum BAFF levels did not correlate with race (or age or sex) in patients with rheumatic diseases. However, because none of the patients in that study were pregnant, pregnant women of varied racial groups and ethnicities will need to be studied to assess the generalizability of our findings. Our study population had a higher incidence of preeclampsia compared with that reported by other investigators. 38, 39 Hispanic women may be at higher risk for including HDP, which could account for some of the increased incidence. 40, 41 Furthermore, our medical center serves an inner-city population, so deleterious social and economic factors may also be contributing. Finally, our results are limited to phenotypically healthy women and need to be reproduced among pregnant women with medical or rheumatic conditions before conclusions can be drawn in those subgroups of pregnant women. Serum BAFF levels are known to be elevated among NP women with rheumatic conditions and in women with other medical conditions. 14, 37 B lymphocytes and protective antibodies are required for a successful pregnancy, whereas altered B-cell functions and alloantibodies have been associated with obstetric complications. 10, 11, 42 The decline in serum BAFF levels with the progression of pregnancy is consistent with the relative immune quiescence in the latter parts of pregnancy and suggests that elevated maternal serum BAFF in early pregnancy may herald an adverse pregnancy event. If confirmed in future studies, our finding that elevated first-trimester serum BAFF levels is associated with the development of HDP may allow for further risk stratification with early intervention and enhanced clinical surveillance for high-risk women.
Perspectives
Belimumab-an anti-BAFF monoclonal antibody-is approved by the US Food and Drug Administration for treatment of systemic lupus erythematosus. To date, the use of belimumab or other BAFF antagonists in pregnancy has not been studied in a controlled manner. Our findings highlight the need for further investigation of BAFF in pregnancy. If further evaluation documents a pathogenic role for BAFF in the development of HDP, then administration of a BAFF antagonist during pregnancy may have a therapeutic role.
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